REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 23, No. 4 (2022)
http://www.veterinaria.org
Article Received: 20 August 2022; Revised: 28 October 2022; Accepted: 05 November 2022

A Research on a Few Oral Hypoglycemic Medications to Stop the Growth of Diabetes Problems in Lab Animals

Ms. Richa[1], Dr. Barun Ranjan Sarkar[2], Mrs. Jyoti Singh Jatav[3], Sabina Gurung[4]

[1]Lecturer, Department of Pharmacy, Usha Martin University, Ranchi- Jharkhand
[2]Assistant Professor, Department of Pharmacy, Himalayan University, Itanagar-Arunachal Pradesh
[3]Assistant Professor, Department of Pharmacy, Mangalayatan University, Aligarh, Uttar Pradesh
[4]Assistant Professor, Collage of Pharmacy, Sikkim Professional University, Gangtok, Sikkim

ABSTRACT

Hyperglycemia is the defining feature of diabetes mellitus (also known as DM), which is a persistent metabolic condition. A deficiency in insulin production (type I) or insulin secretion (type II), together with resistance to the effect of insulin, or a combination of both of these variables, can lead to this syndrome. It is a condition that affects people of all ages, both sexes, and all races equally all over the world. It is a disorder that necessitates the medication-based careful management of one's glucose levels. A dangerously high level of elevated blood glucose (hyperglycemia) can lead to diabetic ketoacidosis, which in turn can cause coma and ultimately death. In a similar vein, low blood glucose, also known as hypoglycemia, can result in a coma and ultimately death. Because of this, it is necessary for the drugs to carefully manage the patient's blood glucose levels. [Cerveny JD et al., 1998] found that people with type II diabetes were more prevalent than those with type I diabetes. Insulin is helpful for diabetics who have type I diabetes. Gliclazide is one of the most commonly prescribed drugs in the category of sulfonylureas, which medications are considered to be the most effective in treating type II diabetes? The medicine Gliclazide served as the benchmark in this particular investigation. Chronic diabetes, if uncontrolled, can lead to a number of consequences, including cardiac difficulties such as angina, hypertension, cardiac dysrhythmias, and renal failure [Cerveny JD et al., 1998]. These complications are the major causes of death in chronic diabetes [Cerveny JD et al., 1998]. [Cerveny JD et al., 1998] The development of various problems, including heart issues such as angina, hypertension, and cardiac dysrhythmia, can be attributed to the presence of diabetes that is chronic.

Keywords *type II diabetes, hyperglycemia, Diabetes mellitus, chronic metabolic disorder, hypertension, cardiac dysrhythmias.*

Introduction:

Background

Diabetes mellitus is a metabolic disorder that is characterised by the presence of hyperglycemia due to either a defect in insulin secretion or a defect in insulin action, or both. Diabetes can also be caused by both of these defects. In addition to an elevated risk for cardiovascular disease, diabetes is linked to relatively specific microvascular problems that develop over the long term and can have an effect on the eyes, kidneys, and nerves. Hyperglycemia that has been present for just a prolonged period of time can be a contributing factor in the development of these problems (CVD). The threshold of glycemic that are linked to microvascular illness, in particular retinopathy, constitute the basis of a clinical guidelines for diabetes. [Case in point:] (Unger RH, 1985)

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 23, No. 4 (2022)
http://www.veterinaria.org
Article Received: 20 August 2022; Revised: 28 October 2022; Accepted: 05 November 2022

LR

The metabolic condition known as diabetes mellitus can be brought on by a wide variety of different factors. Chronic hyperglycemia and abnormalities in the metabolism of carbs, lipids, and proteins are hallmarks of this condition. These metabolic disorders are either caused by a malfunction in the insulin secretion process or the insulin action process, or both of these processes. Diabetes mellitus can cause long-term problems such as damage to several organs, malfunction in the those organs, or even organ damage. Diabetes may be present when specific symptoms are present. These symptoms include dry throat, frequent urination, loss of vision, and a drop in body weight. In its most severe forms, ketosis or a non - ketotic hyperosmolar state can occur, which can subsequently progress to stupor, coma, and eventually death if the illness is not adequately managed. Ketoacidosis can also develop in patients who already have a nonketotic hyperosmolar state.

Diabetes mellitus, the most prevalent endocrine disorder of carbohydrate metabolism, currently affects approximately 8.3% of the world's population (IDF, 2013). According to epidemiologic data, 2.8% of the world's population was diabetic in the year 2000, and there is a possibility that this number will rise to 4.4% of the world's population by the year 2030. (Xing XH, 2009).

There are several different categories of oral hypoglycemic agents that are currently on the market, each of which has its own unique set of adverse effects (Prout, 1974).

Aim & Objective

In order to determine whether or not the combination of certain antipsychotic medications (such as olanzapine, clozapine, risperidone, and ziprasidone) with gliclazide is safethe objectives of this research was to look into the effect that these medications had on the pharmacokinetics and pharmacodynamics of animal models.

The following goals were planned for the research project:

- To investigate how certain antipsychotic drugs affect the pharmacodynamics of gliclazide when administered to normal rats;
- To investigate how certain antipsychotic drugs affect the pharmacodynamics of gliclazide when administered to diabetic rats;
- To investigate how certain antipsychotic drugs affect the pharmacodynamics and pharmacokinetics of gliclazide when administered to normal rabbits.

Hypothesis

- H0. There is no significant change in certain antipsychotic drugs affect the pharmacodynamics of gliclazide when administered to normal rats;
- H1. Tere is significant change in certain antipsychotic drugs affect the pharmacodynamics of gliclazide when administered to normal rats;
- H0. There is no significant change in certain antipsychotic drugs affect the pharmacodynamics of gliclazide when administered to diabetic rats;

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 23, No. 4 (2022)
http://www.veterinaria.org
Article Received: 20 August 2022; Revised: 28 October 2022; Accepted: 05 November 2022

- H2. There is significant change incertain antipsychotic drugs affect the pharmacodynamics of gliclazide when administered to diabetic rats;
- H0. There is no significant change in certain antipsychotic drugs affect the pharmacodynamics and pharmacokinetics of gliclazide when administered to normal rabbits.
- H3. There is significant change in certain antipsychotic drugs affect the pharmacodynamics and pharmacokinetics of gliclazide when administered to normal rabbits.

Material and Method:

Study design

This kit is a convenient and reliable assay system for measuring insulin (human, rabbit, and dog) in serum samples. It can measure insulin in all three species. Insulin and C-peptide are produced as a result of the processing of proinsulin that takes place within the B cell. Equal amounts of insulin and C-peptide are released into the blood circulation during the secretion process.

As a result, measuring the amount of insulin in the blood is extremely important, as it not only provides useful information but also helps evaluate the function of the pancreatic B cells. This kit uses zebra pig pro insulin antibodies (coated onto plate), synthetic hormone calibrator, biotin - conjugated guinea pig anti-human diabetes antibody, plus Horseradish peroxidase streptoavidin to measure insulin concentrations (IR-insulin) in sera from humans, rabbits, and dogs. The plate is then incubated at 37 degrees Celsius for one (SA-HRP). At this point, the activity of the HRP enzyme is measured using the insulin concentration and O-phenylenediaminedihydrochloride (OPD) are computed. The kit's attributes include sensitive measurement, specificity, and also no interference from other sample components.In addition to the necessity of sample pretreatment not being required. Recombinant human insulin calibrator is the product of genetic engineering.

Data collection

Blood samples were collected from the marginal ear veins of the rabbits in order to measure the levels of glucose and gliclazide that were present in the blood of the rabbits. In order to get rabbits ready for this, their heads were left uncovered while they were resting in holders made of wood. The blood vessels were able to be dilated after shaving the left ear for convenience's sake. This was performed by either heating the ears with a reduced electric bulb or rubbing them with a cotton swab. After that, the hair was shaved off of the left ear. In order to puncture the enlarged blood artery of the left peripheral ear vein, a sharp syringe with a gauge of 24 was utilised. This was carried out in the way that blood was moving out of the vein at the time. When collecting the blood, microcentrifuge tubes were employed as the collection device.

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 23, No. 4 (2022)
http://www.veterinaria.org
Article Received: 20 August 2022; Revised: 28 October 2022; Accepted: 05 November 2022

Data analysis

Using the method described above and the equations provided below, we analysed the data showing the concentration of gliclazide in the blood as a function of time. The parameters that were obtained as a result were used in the calculation of the other pharmacokinetic parameters. These parameters include C0 (blood pressure at the moment 0h), Ke (constant elimination rate), and Ka (absorption rate constant). The elimination half-life, denoted by the notation t 1/2, was computed by applying the formula t 1/2 = 0.693/ Kel. The formula for calculating the volume of distribution was "Vd=F x Dose/C0," and the results were as expected. After extrapolating the curve to infinity, the region beneath the plasma gliclazide concentrations vs time curve was calculated using the trapezoidal rule. the region beneath the plasma gliclazide concentrations vs time curve from 0 to 24 hours was then calculated using the same rule.

The formula CL = F x Dose/ AUC 0- was used to calculate total body clearance.

The maximum value of the parameter Tmax was determined by applying the relationship.

Tmax = 2.303 x Log (Ka-Kel) / (Ka-Kel)

Cmax was determined by applying the equation Cmax = (F x Dose/ -Kel x Tmax) to the data.

The area under the first moment curve, also known as AUMC, was determined using the trapezoidal rule. It is a product of the plasma gliclazide concentration multiplied by time (c t) and represents a versus time curve that extends from zero to infinity.

The MRT, also known as the "mean residence time," was determined by applying the formula AUMC/AUC.

Result and Discussion:

In this experiment, normal rabbits were used to investigate how different antipsychotic medications affected the pharmacodynamics and pharmacokinetics of gliclazide at a fixed dose of 5.6 milligrammes per kilogramme of body weight per day. The findings demonstrated that the antipsychotic medications had no influence whatsoever on the pharmacokinetics of the gliclazide. The findings also show that there is contact between two species that are highly distinct from one another; the particulars of this interaction are discussed further down in the paragraph.

A study was conducted on normal rabbits in order to validate the presence or lack of an interaction between certain medicines and Gliclazide in a model that does not involve rodents. In addition, the goal of this investigation was to discover whether the nature of the drug interaction that was found in rats (a rodent model) was pharmacokinetic, pharmacodynamic, or both. since these are among the recognised forms for the insulin bioassay [Goodman LS Gilman A, 2001], because they are easy to care for in a lab, as well as because by perforating the peripheral ear artery, sufficient volumes of specimens can be obtained from them, rabbits were selected for a research project. [Citation needed] [Goodman LS Gilman A, 2001]. At a variety of various time points, the levels of glucose and insulin in the blood, as well as the amount of the reference medicine, will be determined with the help of these samples.

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 23, No. 4 (2022)
http://www.veterinaria.org
Article Received: 20 August 2022; Revised: 28 October 2022; Accepted: 05 November 2022

Conclusion:

The current study aims to establish the safety of atypical antipsychotic medicines of selected drugs (olanzapine, clozapine, risperidone, and ziprasidone), as well as the safety of their combination with gliclazide, with regard to the assessment of blood glucose and serum insulin in animal models. The purpose of the study was to investigate whether or not these medications pose any health risks.

The research was carried out on two distinct species of animals, one of which was a rodent (normal rats and diabetic rats), and the other was not a rodent (typical rabbits), with the idea that if a connection occurs between two different species, it is probably also going to happen between humans. as well. If the mixture was found to be secure in two different species that have quite different physiologies, then it is highly likely that it is also safe for humans.

Both the normal rat model and the diabetic rat model were utilised in order to immediately discover the interaction. Additionally, the diabetic rat model was utilised in order to validate the same response in the context of real-world drug usage situations.

References:

[1]. Unger RH. Grundy Hyperglycemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia. 1985; 28: 119-121

[2]. IDF Diabetes Atlas, International diabetes federation. 6th Edition, 2013

[3]. Xing XH, Zhang ZM, Hu XZ, Wu RQ, Xu C. Antidiabetic effects of Artemisia sphaerocephalaKrasch. gum, a novel food additive in China, on streptozotocin-induced type 2 diabetic rats. J Ethnopharmacol. 2009; 125(3):410-6

[4]. Prout TE. In: Malaisse WJ, Pirart J. Procedings (VIII) of Congress of International Diabetes Federation. Excerptamedica. 1974; 162

[5]. American Geriatrics Society Beers Criteria Update Expert Panel (2012). "American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults". J Am Geriatr Soc. 2012; 60 (4): 616–31.

[6]. Baldessarini Ross J, Frank I. Tarazi Pharmacotherapy of Psychosis and Maa. In Laurence Brunton, John Lazo, Keith Parker (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th ed.), 2006

[7]. Campbell DB, Lavielle R & Nathan C: The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res ClinPract. 1991; 14(2):21-36.

[8]. De Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ: Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001; 63 : 619-630.

[9]. Wirshing DA, Wirshing WC, Kysar L, Berisford MA. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychol. 1999; 60 (6): 358–63.

[10]. Xing XH, Zhang ZM, Hu XZ, Wu RQ, Xu C. Antidiabetic effects of Artemisia sphaerocephalaKrasch. gum, a novel food additive in China, on streptozotocin-induced type 2 diabetic rats. J Ethnopharmacol. 2009; 125(3):410-6

[11]. Yoon JW and Baek HS. Role of macrophages in the pathogenesis of encephalomyocarditis virus-induced diabetes in mice. J Virol. 1990 Dec; 64(12): 5708–5715.